Meeting
2012 ASCO Annual Meeting
Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temozolomide.
Authors
Manfred Westphal
Department of Neurosurgery, UKE Hamburg, Hamburg, Germany
Manfred Westphal , Ferdinand Bach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NTC 00753246
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2033)
DOI
10.1200/jco.2012.30.15_suppl.2033
Abstract #
2033
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
First Author: Patrick Roth
Poster
2021 ASCO Annual Meeting
Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
First Author: Louis B. Nabors
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi
Poster
2017 ASCO Annual Meeting
Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Phioanh Leia Nghiemphu